Concepts (245)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Nail Diseases | 42 | 2024 | 49 | 15.090 |
Why?
|
| Skin Neoplasms | 43 | 2024 | 398 | 11.520 |
Why?
|
| Nails | 24 | 2022 | 38 | 6.410 |
Why?
|
| Surgical Flaps | 14 | 2021 | 110 | 5.570 |
Why?
|
| Mohs Surgery | 19 | 2021 | 52 | 4.740 |
Why?
|
| Melanoma | 15 | 2022 | 318 | 4.380 |
Why?
|
| Surgical Wound | 4 | 2020 | 10 | 2.260 |
Why?
|
| Dermatologic Surgical Procedures | 8 | 2021 | 34 | 2.110 |
Why?
|
| Dermatology | 6 | 2024 | 70 | 2.010 |
Why?
|
| Carcinoma, Basal Cell | 8 | 2021 | 64 | 1.980 |
Why?
|
| Papilloma | 4 | 2020 | 12 | 1.920 |
Why?
|
| Foot Dermatoses | 4 | 2016 | 5 | 1.850 |
Why?
|
| Carcinoma, Squamous Cell | 7 | 2022 | 237 | 1.730 |
Why?
|
| Fingers | 4 | 2019 | 43 | 1.700 |
Why?
|
| Toes | 6 | 2021 | 13 | 1.630 |
Why?
|
| Nails, Malformed | 2 | 2024 | 6 | 1.580 |
Why?
|
| Rhinoplasty | 3 | 2018 | 10 | 1.410 |
Why?
|
| Humans | 86 | 2024 | 59457 | 1.350 |
Why?
|
| Ganglion Cysts | 2 | 2021 | 4 | 1.350 |
Why?
|
| Onychomycosis | 3 | 2015 | 6 | 1.330 |
Why?
|
| Nose | 4 | 2016 | 28 | 1.320 |
Why?
|
| Biopsy | 13 | 2021 | 410 | 1.230 |
Why?
|
| Lip Neoplasms | 3 | 2020 | 4 | 1.180 |
Why?
|
| Nose Neoplasms | 5 | 2014 | 17 | 1.150 |
Why?
|
| Anesthesia, Local | 4 | 2016 | 20 | 1.120 |
Why?
|
| Dermoscopy | 4 | 2017 | 11 | 1.080 |
Why?
|
| Postoperative Complications | 3 | 2021 | 1204 | 0.950 |
Why?
|
| Antifungal Agents | 2 | 2015 | 120 | 0.930 |
Why?
|
| Cicatrix | 3 | 2020 | 59 | 0.920 |
Why?
|
| Lip | 2 | 2020 | 13 | 0.890 |
Why?
|
| Diagnosis, Differential | 11 | 2024 | 934 | 0.880 |
Why?
|
| Facial Nerve Injuries | 1 | 2021 | 4 | 0.750 |
Why?
|
| Professional Practice Gaps | 1 | 2021 | 4 | 0.750 |
Why?
|
| Nails, Ingrown | 1 | 2021 | 1 | 0.740 |
Why?
|
| Current Procedural Terminology | 1 | 2021 | 16 | 0.740 |
Why?
|
| Tubulin Modulators | 1 | 2021 | 6 | 0.740 |
Why?
|
| Facial Paralysis | 1 | 2021 | 12 | 0.740 |
Why?
|
| Male | 27 | 2024 | 27784 | 0.710 |
Why?
|
| Lacrimal Apparatus | 1 | 2020 | 3 | 0.700 |
Why?
|
| Middle Aged | 19 | 2021 | 16338 | 0.700 |
Why?
|
| Scalp | 3 | 2016 | 29 | 0.700 |
Why?
|
| Eye Neoplasms | 1 | 2020 | 17 | 0.700 |
Why?
|
| Anesthetics, Local | 3 | 2016 | 68 | 0.690 |
Why?
|
| Arteries | 1 | 2020 | 76 | 0.680 |
Why?
|
| Glomus Tumor | 1 | 2020 | 2 | 0.670 |
Why?
|
| Splints | 1 | 2019 | 5 | 0.670 |
Why?
|
| Aged | 19 | 2021 | 13427 | 0.660 |
Why?
|
| Hand Deformities, Acquired | 1 | 2019 | 2 | 0.650 |
Why?
|
| Organ Sparing Treatments | 1 | 2019 | 15 | 0.650 |
Why?
|
| Lichen Planus | 3 | 2024 | 9 | 0.640 |
Why?
|
| Female | 27 | 2024 | 30766 | 0.640 |
Why?
|
| Lasers, Dye | 1 | 2018 | 6 | 0.580 |
Why?
|
| Trichophyton | 2 | 2015 | 4 | 0.580 |
Why?
|
| Lasers, Solid-State | 1 | 2018 | 10 | 0.580 |
Why?
|
| Prostatic Neoplasms | 1 | 2021 | 339 | 0.580 |
Why?
|
| Forehead | 2 | 2014 | 16 | 0.580 |
Why?
|
| Wound Healing | 3 | 2016 | 174 | 0.570 |
Why?
|
| Carcinoma in Situ | 2 | 2016 | 33 | 0.560 |
Why?
|
| Treatment Outcome | 9 | 2021 | 5287 | 0.520 |
Why?
|
| Melanosis | 2 | 2020 | 9 | 0.510 |
Why?
|
| Triamcinolone Acetonide | 1 | 2016 | 13 | 0.500 |
Why?
|
| Drug Resistance, Multiple, Fungal | 1 | 2015 | 4 | 0.500 |
Why?
|
| Nerve Block | 2 | 2016 | 41 | 0.480 |
Why?
|
| Triazoles | 1 | 2015 | 51 | 0.480 |
Why?
|
| Fibroma | 1 | 2015 | 12 | 0.480 |
Why?
|
| Head and Neck Neoplasms | 1 | 2016 | 148 | 0.470 |
Why?
|
| Hemangioendothelioma | 1 | 2014 | 5 | 0.470 |
Why?
|
| Esthetics | 4 | 2020 | 18 | 0.470 |
Why?
|
| Lipoma | 1 | 2014 | 17 | 0.470 |
Why?
|
| Foot Deformities | 1 | 2014 | 1 | 0.470 |
Why?
|
| Shoes | 1 | 2014 | 13 | 0.460 |
Why?
|
| Thumb | 4 | 2020 | 27 | 0.460 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2014 | 31 | 0.460 |
Why?
|
| Lasers, Gas | 1 | 2014 | 2 | 0.460 |
Why?
|
| Betamethasone | 1 | 2014 | 5 | 0.450 |
Why?
|
| Onycholysis | 1 | 2014 | 2 | 0.450 |
Why?
|
| Glucocorticoids | 1 | 2016 | 180 | 0.450 |
Why?
|
| Steroids | 1 | 2014 | 52 | 0.450 |
Why?
|
| Calcitriol | 1 | 2014 | 24 | 0.450 |
Why?
|
| Dermatologic Agents | 1 | 2014 | 20 | 0.450 |
Why?
|
| Tourniquets | 1 | 2013 | 5 | 0.420 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2019 | 693 | 0.420 |
Why?
|
| Paraneoplastic Syndromes | 2 | 2010 | 11 | 0.410 |
Why?
|
| Frozen Sections | 1 | 2012 | 10 | 0.410 |
Why?
|
| Anti-Inflammatory Agents | 2 | 2014 | 164 | 0.410 |
Why?
|
| Orthopedic Procedures | 1 | 2013 | 41 | 0.400 |
Why?
|
| Suture Techniques | 1 | 2013 | 92 | 0.390 |
Why?
|
| Adult | 10 | 2020 | 15697 | 0.390 |
Why?
|
| Follow-Up Studies | 5 | 2020 | 2341 | 0.390 |
Why?
|
| Aged, 80 and over | 8 | 2020 | 5129 | 0.380 |
Why?
|
| Ischemia | 1 | 2013 | 199 | 0.360 |
Why?
|
| Retrospective Studies | 7 | 2020 | 6082 | 0.360 |
Why?
|
| Patient Education as Topic | 1 | 2014 | 453 | 0.350 |
Why?
|
| Nevus, Blue | 1 | 2008 | 2 | 0.300 |
Why?
|
| Dermabrasion | 1 | 2008 | 1 | 0.300 |
Why?
|
| Cheilitis | 1 | 2008 | 5 | 0.300 |
Why?
|
| Precancerous Conditions | 2 | 2008 | 70 | 0.300 |
Why?
|
| Melanoma, Amelanotic | 1 | 2008 | 2 | 0.300 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2008 | 29 | 0.290 |
Why?
|
| Internship and Residency | 1 | 2015 | 748 | 0.280 |
Why?
|
| Pigmentation Disorders | 1 | 2007 | 8 | 0.280 |
Why?
|
| Coronavirus Infections | 2 | 2020 | 192 | 0.270 |
Why?
|
| Skin Transplantation | 2 | 2018 | 155 | 0.270 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 205 | 0.270 |
Why?
|
| Clinical Competence | 2 | 2021 | 683 | 0.270 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2021 | 300 | 0.270 |
Why?
|
| Hematoma | 1 | 2007 | 68 | 0.270 |
Why?
|
| Tinea Pedis | 1 | 2006 | 3 | 0.270 |
Why?
|
| Epidermal Cyst | 1 | 2006 | 11 | 0.270 |
Why?
|
| Epinephrine | 3 | 2016 | 41 | 0.260 |
Why?
|
| Melanocytes | 1 | 2007 | 77 | 0.260 |
Why?
|
| Skin Diseases | 1 | 2006 | 76 | 0.250 |
Why?
|
| Cheek | 2 | 2021 | 5 | 0.250 |
Why?
|
| Wounds and Injuries | 1 | 2008 | 229 | 0.250 |
Why?
|
| Administration, Cutaneous | 2 | 2015 | 26 | 0.250 |
Why?
|
| Plants, Medicinal | 1 | 2005 | 60 | 0.240 |
Why?
|
| Phytotherapy | 1 | 2005 | 52 | 0.240 |
Why?
|
| Bibliometrics | 1 | 2004 | 27 | 0.220 |
Why?
|
| Naphthalenes | 2 | 2015 | 18 | 0.210 |
Why?
|
| Pain | 2 | 2016 | 397 | 0.200 |
Why?
|
| Injections, Intralesional | 2 | 2016 | 12 | 0.200 |
Why?
|
| Dermatologists | 1 | 2021 | 12 | 0.190 |
Why?
|
| Betacoronavirus | 2 | 2020 | 166 | 0.190 |
Why?
|
| Periodicals as Topic | 1 | 2004 | 166 | 0.180 |
Why?
|
| Air Pollutants, Occupational | 1 | 2021 | 73 | 0.180 |
Why?
|
| Finger Joint | 1 | 2021 | 9 | 0.180 |
Why?
|
| Nasolabial Fold | 1 | 2020 | 1 | 0.180 |
Why?
|
| Mentors | 1 | 2021 | 116 | 0.170 |
Why?
|
| Surveys and Questionnaires | 2 | 2021 | 2517 | 0.170 |
Why?
|
| Consensus | 1 | 2021 | 193 | 0.170 |
Why?
|
| Biopsy, Needle | 2 | 2010 | 134 | 0.170 |
Why?
|
| Immunohistochemistry | 3 | 2010 | 851 | 0.170 |
Why?
|
| Clinical Decision-Making | 1 | 2020 | 148 | 0.160 |
Why?
|
| Surgical Procedures, Operative | 2 | 2010 | 137 | 0.150 |
Why?
|
| Pandemics | 2 | 2020 | 617 | 0.150 |
Why?
|
| Pain, Postoperative | 1 | 2019 | 141 | 0.150 |
Why?
|
| Occupational Exposure | 1 | 2021 | 307 | 0.150 |
Why?
|
| Drug Prescriptions | 1 | 2019 | 168 | 0.150 |
Why?
|
| Hair Removal | 1 | 2018 | 8 | 0.150 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2019 | 127 | 0.150 |
Why?
|
| Vasoconstrictor Agents | 2 | 2016 | 64 | 0.140 |
Why?
|
| Laser Therapy | 1 | 2018 | 36 | 0.140 |
Why?
|
| Adenocarcinoma, Papillary | 1 | 2017 | 9 | 0.140 |
Why?
|
| Psoriasis | 1 | 2018 | 50 | 0.140 |
Why?
|
| Delayed Diagnosis | 1 | 2016 | 42 | 0.120 |
Why?
|
| Pyridones | 1 | 2015 | 37 | 0.120 |
Why?
|
| 12E7 Antigen | 1 | 2015 | 2 | 0.120 |
Why?
|
| Neoplasm Metastasis | 1 | 2016 | 186 | 0.120 |
Why?
|
| Mucin-1 | 1 | 2015 | 14 | 0.120 |
Why?
|
| Antigens, CD34 | 1 | 2015 | 54 | 0.120 |
Why?
|
| Adolescent | 2 | 2016 | 5851 | 0.120 |
Why?
|
| Physicians | 1 | 2020 | 442 | 0.120 |
Why?
|
| Severity of Illness Index | 2 | 2020 | 1482 | 0.120 |
Why?
|
| Analgesics, Opioid | 1 | 2019 | 487 | 0.120 |
Why?
|
| Bandages | 1 | 2014 | 15 | 0.120 |
Why?
|
| Cell Adhesion Molecules | 1 | 2015 | 85 | 0.110 |
Why?
|
| Needles | 1 | 2015 | 65 | 0.110 |
Why?
|
| Administration, Oral | 1 | 2015 | 355 | 0.110 |
Why?
|
| Time Factors | 1 | 2021 | 3621 | 0.110 |
Why?
|
| Temperature | 1 | 2015 | 296 | 0.110 |
Why?
|
| Antigens, CD | 1 | 2015 | 343 | 0.110 |
Why?
|
| Double-Blind Method | 1 | 2015 | 715 | 0.110 |
Why?
|
| Ambulatory Care | 1 | 2016 | 305 | 0.110 |
Why?
|
| Algorithms | 2 | 2010 | 979 | 0.110 |
Why?
|
| Dioxanes | 1 | 2013 | 4 | 0.110 |
Why?
|
| Polyglactin 910 | 1 | 2013 | 6 | 0.110 |
Why?
|
| Carcinoma, Verrucous | 1 | 2012 | 3 | 0.100 |
Why?
|
| Sutures | 1 | 2013 | 35 | 0.100 |
Why?
|
| Health Surveys | 1 | 2014 | 299 | 0.100 |
Why?
|
| Quality of Life | 1 | 2020 | 1138 | 0.100 |
Why?
|
| Polyesters | 1 | 2013 | 46 | 0.100 |
Why?
|
| Prognosis | 1 | 2015 | 1597 | 0.090 |
Why?
|
| Patient Selection | 1 | 2013 | 465 | 0.090 |
Why?
|
| Photography | 2 | 2020 | 40 | 0.090 |
Why?
|
| Prevalence | 1 | 2014 | 1258 | 0.090 |
Why?
|
| Itraconazole | 1 | 2010 | 13 | 0.090 |
Why?
|
| Eyelid Neoplasms | 1 | 2010 | 9 | 0.080 |
Why?
|
| Carcinoma, Merkel Cell | 1 | 2010 | 8 | 0.080 |
Why?
|
| Risk Factors | 3 | 2016 | 4990 | 0.080 |
Why?
|
| Inflammation | 1 | 2016 | 1099 | 0.080 |
Why?
|
| Hutchinson's Melanotic Freckle | 1 | 2008 | 5 | 0.080 |
Why?
|
| Recurrence | 1 | 2010 | 603 | 0.070 |
Why?
|
| Foreign Bodies | 1 | 2008 | 44 | 0.070 |
Why?
|
| Plasma Cells | 1 | 2008 | 49 | 0.070 |
Why?
|
| Postoperative Hemorrhage | 1 | 2008 | 37 | 0.070 |
Why?
|
| Reagent Strips | 1 | 2007 | 5 | 0.070 |
Why?
|
| Skin Pigmentation | 1 | 2007 | 29 | 0.070 |
Why?
|
| Hyperplasia | 1 | 2007 | 85 | 0.070 |
Why?
|
| United States | 2 | 2014 | 7432 | 0.070 |
Why?
|
| Fibrinolytic Agents | 1 | 2008 | 163 | 0.070 |
Why?
|
| Arthrodermataceae | 1 | 2006 | 1 | 0.070 |
Why?
|
| Disease Reservoirs | 1 | 2006 | 9 | 0.070 |
Why?
|
| Syndrome | 1 | 2006 | 170 | 0.070 |
Why?
|
| Fibrosis | 1 | 2006 | 153 | 0.060 |
Why?
|
| Candida albicans | 1 | 2006 | 69 | 0.060 |
Why?
|
| Organ Transplantation | 1 | 2006 | 53 | 0.060 |
Why?
|
| Calcinosis | 1 | 2006 | 79 | 0.060 |
Why?
|
| Sanguinaria | 1 | 2005 | 2 | 0.060 |
Why?
|
| Rumex | 1 | 2005 | 2 | 0.060 |
Why?
|
| Trifolium | 1 | 2005 | 3 | 0.060 |
Why?
|
| Ointments | 1 | 2005 | 7 | 0.060 |
Why?
|
| Surgical Instruments | 1 | 2005 | 41 | 0.060 |
Why?
|
| Practice Guidelines as Topic | 2 | 2020 | 706 | 0.060 |
Why?
|
| Young Adult | 1 | 2015 | 4274 | 0.060 |
Why?
|
| Treatment Failure | 1 | 2005 | 185 | 0.060 |
Why?
|
| Complementary Therapies | 1 | 2005 | 56 | 0.060 |
Why?
|
| Radiography | 1 | 2006 | 518 | 0.060 |
Why?
|
| Phenotype | 1 | 2008 | 1138 | 0.060 |
Why?
|
| Europe | 1 | 2024 | 182 | 0.050 |
Why?
|
| History, 21st Century | 1 | 2024 | 162 | 0.050 |
Why?
|
| History, 20th Century | 1 | 2024 | 224 | 0.050 |
Why?
|
| Prospective Studies | 1 | 2010 | 3072 | 0.050 |
Why?
|
| Conservative Treatment | 1 | 2022 | 15 | 0.050 |
Why?
|
| Cohort Studies | 1 | 2008 | 2377 | 0.050 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2022 | 38 | 0.050 |
Why?
|
| Beauty Culture | 1 | 2021 | 15 | 0.050 |
Why?
|
| Neoplasm Staging | 1 | 2022 | 448 | 0.040 |
Why?
|
| Internationality | 1 | 2020 | 43 | 0.040 |
Why?
|
| Educational Status | 1 | 2021 | 264 | 0.040 |
Why?
|
| Personal Protective Equipment | 1 | 2020 | 29 | 0.040 |
Why?
|
| Morbidity | 1 | 2020 | 113 | 0.040 |
Why?
|
| Office Visits | 1 | 2020 | 42 | 0.040 |
Why?
|
| Video Recording | 1 | 2020 | 126 | 0.040 |
Why?
|
| Time-to-Treatment | 1 | 2020 | 98 | 0.040 |
Why?
|
| Immunocompromised Host | 1 | 2020 | 101 | 0.040 |
Why?
|
| Self Report | 1 | 2021 | 359 | 0.040 |
Why?
|
| Infection Control | 1 | 2020 | 95 | 0.040 |
Why?
|
| Program Evaluation | 1 | 2021 | 470 | 0.040 |
Why?
|
| Skin | 1 | 2020 | 357 | 0.040 |
Why?
|
| Comorbidity | 1 | 2020 | 1078 | 0.030 |
Why?
|
| Neoplasms | 1 | 2006 | 1232 | 0.030 |
Why?
|
| Hyaluronoglucosaminidase | 1 | 2016 | 4 | 0.030 |
Why?
|
| Sodium Bicarbonate | 1 | 2016 | 11 | 0.030 |
Why?
|
| Administration, Topical | 1 | 2016 | 48 | 0.030 |
Why?
|
| Patient Preference | 1 | 2016 | 78 | 0.030 |
Why?
|
| Telemedicine | 1 | 2020 | 310 | 0.030 |
Why?
|
| Evidence-Based Medicine | 1 | 2016 | 443 | 0.030 |
Why?
|
| Keratin-20 | 1 | 2010 | 1 | 0.020 |
Why?
|
| Chromogranin A | 1 | 2010 | 7 | 0.020 |
Why?
|
| Epidermis | 1 | 2010 | 35 | 0.020 |
Why?
|
| Triamcinolone | 1 | 2008 | 2 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2008 | 451 | 0.020 |
Why?
|
| Chemoprevention | 1 | 2006 | 39 | 0.020 |
Why?
|
| Endarterectomy | 1 | 2005 | 18 | 0.020 |
Why?
|
| Equipment Design | 1 | 2005 | 330 | 0.010 |
Why?
|